BioTelemetry, Inc. — Cyborg Score 7/10

Strong
Biotechnology Research / Connected Health

Strategic Profile

BioTelemetry maintains market leadership in remote cardio diagnostics through proprietary technology and strong customer relationships. As part of Philips, it benefits from integrated distribution networks and access to broader healthcare solutions, positioning it to expand bundled remote monitoring and cardiac care offerings across enterprise healthcare systems.

Cyborg Score Rationale

BioTelemetry demonstrates solid market positioning in remote cardiac monitoring with established revenue streams and a presence across multiple continents. Ownership by Philips provides financial stability and integration opportunities, though independent growth metrics are limited post-acquisition.

Top Insights

  • (March 2026) Annual revenue estimated at $179M with 614 employees across 4 continents
  • (2021) Strategic acquisition by Philips significantly expanded cardiac care offerings and market integration
  • Founded 25 years ago with leadership in mobile and wireless medical technology
  • Specializes in remote monitoring solutions and clinical research for cardiac and imaging applications

Named Competitors

  • Remote Patient Monitoring Solutions — Connected cardiac care and patient monitoring
  • Connected Care Services — Integrated cardiac device and monitoring solutions
  • Philips Remote Monitoring — Parent company's integrated healthcare monitoring platform

Recent Developments

  • (March 2026) Revenue estimated at $179M with 614 employees globally
  • (2021) Acquired by Philips, integrating into Philips' healthcare technology portfolio

Open the full interactive BioTelemetry, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →